Alpha Talon Investment Research
Subscribe
Sign in
Home
Notes
Power, Policy & Markets
Guides to Investing
Letters and Reflection
ATIR Portfolios
Asia Market
Industry Analysis
Good Quality High Dividend
Deep Value
IT
BioPharma Healthcare
Special Situation
M&A
Short Thesis
Archive
Newsletters
Leaderboard
About
Special Situation
Latest
Top
Discussions
The Strait and the Strike: A Game-Theory Map of the Middle East Escalation
A scenario-based probabilistic framework for U.S.-Israel-Iran decisions, Gulf incentives, and global macro risk premia and choke points.
Mar 3
•
AT Investment Research
11
1
1
Chicago Rivet & Machine Co. (NYSEAMERICAN: CVR): When “Cheap” Becomes a Cage
Why asset backing, family control, and cyclical earnings turn CVR into a value trap for minority shareholders
Jan 26
•
AT Investment Research
14
1
Nike, Inc. (NYSE: NKE): A Franchise Reset, Not A Value Trap
Why execution discipline, not growth narratives, will determine Nike’s next cycle of returns AT Investment Research
Jan 13
•
AT Investment Research
12
3
Fiserv: Execution Reset in a Durable Payments Franchise
Why a 2025 Operating Leverage Breakdown Has Created a Mispriced Infrastructure Compounder And What Needs to Normalize for Re-Rating
Jan 6
•
AT Investment Research
8
2
1
A Trip Down Memory Lane: An Anatomy of a Perfect Luxury Mispricing
Revisiting My Burberry Plc Investment — A Masterclass in Brand Equity, Optionality, and Timing
Dec 1, 2025
•
AT Investment Research
2
Sarepta Therapeutics (NASDAQ:SRPT): From Hype to Hard Reality — A Binary Bet on Survival, Not Sympathy
ESSENCE broke the story, not the balance sheet. $865M cash, $2B sales, $400M cuts — Sarepta trades below liquidation as FDA holds its fate
Nov 4, 2025
•
AT Investment Research
3
10
6
Porsche AG (P911): Where Engineering Heritage Meets Market Amnesia
A Luxury Franchise Trapped in Cyclical Valuation. Margins at the Bottom, Execution at the Turn. This Is Why the Next Five Years Could Deliver 90 Percent…
Oct 31, 2025
•
AT Investment Research
2
1
Beyond Survival: The Last Stand of Beyond Meat (NASDAQ: BYND)
A forensic look at the company’s capital structure, solvency math, and whether a 97% dilution was the necessary purge before rebirth.
Oct 20, 2025
•
AT Investment Research
1
Lululemon (NASDAQ: LULU): A Premium Brand at a Discount Multiple
Is Wall Street and Main Street underestimating the company’s turnaround potential?
Sep 30, 2025
•
AT Investment Research
4
UnitedHealth’s $242B Gut Check: Crisis, Comeback, or Value Trap
Executive Summary
Aug 13, 2025
•
AT Investment Research
1
Sarepta Therapeutics (SRPT) Update
Q2 Earnings with Key Metrics
Aug 8, 2025
•
AT Investment Research
SRPT Part 2 — Elevidys at a Crossroads: Safety Signal or Regulatory Overreach?
FDA considers new trials after non-ambulatory deaths. But in ambulatory patients, the safety profile holds—and the principle of accelerated approval is…
Jul 25, 2025
•
AT Investment Research
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
